Effect of a new antisense oligodeoxyribonucleotide, HA824, targeting at HER-2 mRNA on HER-2 expression

Chinese Journal of Pharmacology and Toxicology

Volumn 17, Issue 2, 2003, Pages 87-92

  Yang, Shuan Ping ^a   Song, San Tai ^a   Song, Hai Feng ^a   Zheng, Xiao Ling ^a   Tang, Zhong Ming ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Gene expression; Oligodeoxyribonucleotides, antisense; Oncogenes, HER 2; Protein expression

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; HA 4; HA 824; MESSENGER RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0038369918     PISSN: 10003002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Yang SP, Song ST, Song HF. The advancements of antisense oligonucleotides in treatment of breast cancer[J]. Acta Pharmacol Sin, 2003, 24(4): 289-295.
2. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185 000-Mr tumour antigen[J]. Nature, 1984, 312(5994):513-516.
3. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma[J]. J Cell Physiol, 2000, 182(2):150-162.
4. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells[J]. Oncogene, 1997, 15(5):537-547.
5. Miles DW. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting[J]. Breast Cancer Res, 2001, 3(6):380-384.
6. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling [J]. Mol Cell Biol, 1995, 15(3):1182-1191.
7. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC. Soluble HER2/neu neutralizes biologic effects of anti-HER2/neu antibody on breast cancer cell in vitro[J]. Int J Cancer, 1997, 73(6):875-879.
8. Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam N, et al. HER2/neu antisense targeting of human breast carcinoma [J]. Oncogene, 2000, 19(53): 6138-6143.
9. Song HF, Tang ZM, Yuan SJ, Zhu BZ. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis[J]. Acta Pharmacol Sin, 2000, 21(1):80-86.
10. Yang SP, Song ST, Tang ZM, Song HF. Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis[J]. Acta Pharmacol Sin, 2003 (in press).
11. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, et al. Overexpression of HER-2/neu in uterine serous papillary cancer[J]. Clin Cancer Res, 2002, 8(5): 1271-1279.
12. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hollenstein U, Lucas T, et al. A phase I - II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (Genta) as a chemosensitizer in patients with advanced malignant melanoma(Abstract)[J]. Proc Am Assoc Clin Oncol, 1999, 18:2049.
13. Srivastava RK, Srivastava AR, Seth P, Agrawal S, Cho-Chung YS. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action [J]. Mol Cell Biochem, 1999, 195(1-2):25-36.
14. Yang DC, Jiang XP, Elliott RL, Head JF. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene[J]. Anticancer Res, 2001, 21(3B):1777-1787.
15. Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents[J]. Surgery, 1999, 126(2):413-421.